目的 优化柚皮素磷脂酰胆碱复合物滴丸（naringenin-phosphatidylcholine complex dropping pills，Nar-PC-DPs）处方，考察口服药动学行为及生物利用度。方法 溶剂挥发法制备柚皮素磷脂酰胆碱复合物（naringenin-phosphatidylcholine complex，Nar-PC）。采用成型率和丸重差异为指标，单因素实验联合Box-Behnken效应面法筛选Nar-PC-DPs处方。扫描电子显微镜（SEM）观察Nar-PC-DPs微观形态，X射线粉末衍射法（XRPD）分析柚皮素在Nar-PC-DPs中存在状态，测定Nar-PC-DPs溶解度和体外释药情况。比格犬分别给予柚皮素原料药、Nar-PC和Nar-PC-DPs，测定血药浓度，计算主要药动学参数。结果 Nar-PC-DPs最佳处方工艺为聚乙二醇4000（PEG 4000）占基质百分比为49%，基质与Nar-PC质量比为5.2：1，滴距为8.2 cm。Nar-PC-DPs外观圆整、光滑。柚皮素在Nar-PC-DPs中以无定型形式存在，在不同介质中溶解度均明显增加。Nar-PC-DPs在60 min内累积溶出度为95.10%，储存稳定性良好。药动学结果显示，Nar-PC-DPs的达峰时间（tmax）提前至（0.95±0.14）h，半衰期（t1/2）增加至（6.85±0.71）h，达峰浓度（Cmax）增加至3.25倍，相对口服吸收生物利用提高至3.79倍。结论 Nar-PC-DPs增加了柚皮素溶解度，促进了药物溶出，提高了口服吸收生物利用度。
Objective To optimize prescriptions of naringenin-phosphatidylcholine complex dropping pills (Nar-PC-DPs), and investigate its oral pharmacokinetic behavior and bioavailability. Methods Solvent evaporation method was employed to prepare naringenin-phosphatidylcholine complex (Nar-PC). Forming rate and weight difference were used as indexes, single factor investigation combined with Box-Behnken design response surface method was employed to investigate the optimal prescriptions of Nar-PC-DPs. Microscopic morphology of Nar-PC-DPs was observed by scanning electron microscope (SEM). Crystal form of naringenin in Nar-PC-DPs was analyzed by X ray powder diffraction (XRPD). Solubility and in vitro release behavior of Nar-PC-DPs were determined. Beagle dogs were administrated of naringenin suspension, Nar-PC and Nar-PC-DPs, respectively. Plasma concentrations were determined, and main pharmacokinetic parameters were calculated. Results Optimum prescriptions of Nar-PC-DPs:percentage of PEG 4000 in matrix was 49%, matrix to Nar-PC ratio was 5.2:1, dropping distance was 8.2 cm. Appearance of Nar-PC-DPs was round and smooth. Naringenin existed as an amorphous form in Nar-PC-DPs, and solubility in different media was enhanced greatly. Cumulative dissolution of Nar-PC-DPs reached 95.10% in 60 min, and storage stability was perfect. Pharmacokinetic results showed that the time to peak (tmax) of Nar-PC-DPs was shift to (0.95 ±0.14) h, half-life period (t1/2) was extend to (6.85 ±0.71) h, peak concentration (Cmax) was increased to 3.25 times and oral bioavailability was enhanced to 3.79 times. Conclusion Nar-PC-DPs increased the solubility of naringenin, promoted the drug dissolution and enhanced oral bioavailability.